NovoCure (NASDAQ:NVCR) CFO Christoph Brackmann Sells 6,412 Shares

NovoCure Limited (NASDAQ:NVCR) CFO Christoph Brackmann sold 6,412 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $85,343.72. Following the completion of the transaction, the chief financial officer directly owned 182,842 shares of the company’s stock, valued at approximately $2,433,627.02. This represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

NovoCure Price Performance

NVCR traded down $1.05 on Friday, hitting $13.18. 526,560 shares of the company’s stock were exchanged, compared to its average volume of 2,192,362. NovoCure Limited has a fifty-two week low of $9.82 and a fifty-two week high of $21.55. The company has a current ratio of 2.90, a quick ratio of 1.50 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $12.75 and a 200-day moving average price of $12.71. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -10.80 and a beta of 0.71.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19. The firm had revenue of $174.35 million for the quarter, compared to the consensus estimate of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same period last year, the firm posted ($0.61) earnings per share. As a group, equities analysts anticipate that NovoCure Limited will post -1.3 earnings per share for the current year.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Quarterly results showed an EPS beat and revenue growth (year-over-year revenue +8.2%), which supports fundamentals and was cited by analysts when updating models. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive: HC Wainwright raised its price target and several analysts maintain Buy ratings or higher targets, providing upside cases versus the current share price. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerages’ consensus rating is “Hold,” indicating limited near‑term conviction for a re‑rating; consensus target remains well above the current price, which creates a mixed signal for investors. NovoCure receives average “Hold” rating
• Neutral Sentiment: Institutional ownership is high (reported ~84.6%), which can reduce free‑float volatility but also means insider moves may attract outsized attention. Institutional holdings (MarketBeat)
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k at ~$12.98), trimming his stake by ~18% — a sizable single insider sale that the market interprets as a negative signal. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO, CEO, CFO and other insiders) executed notable sales over the same period — a pattern that amplifies negative sentiment and likely pressured the stock intraday. Aggregated filings and coverage of these insider transactions are available. Insider trades summary (MarketBeat)

Hedge Funds Weigh In On NovoCure

Hedge funds have recently made changes to their positions in the stock. Arizona State Retirement System lifted its holdings in shares of NovoCure by 3.0% during the 3rd quarter. Arizona State Retirement System now owns 31,313 shares of the medical equipment provider’s stock valued at $405,000 after acquiring an additional 916 shares in the last quarter. Larson Financial Group LLC raised its position in NovoCure by 25.2% in the fourth quarter. Larson Financial Group LLC now owns 5,133 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 1,033 shares during the period. Alliancebernstein L.P. raised its position in NovoCure by 0.8% in the third quarter. Alliancebernstein L.P. now owns 137,106 shares of the medical equipment provider’s stock valued at $1,771,000 after purchasing an additional 1,076 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of NovoCure by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 1,120 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of NovoCure by 14.9% in the fourth quarter. Royal Bank of Canada now owns 12,830 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 1,667 shares during the period. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. HC Wainwright lifted their price target on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Evercore set a $20.00 price target on shares of NovoCure in a research report on Monday, January 5th. Finally, Wedbush restated a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a research report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $26.93.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.